Cargando…

Baseline Cytokine Profile Identifies a Favorable Outcome in a Subgroup of Colorectal Cancer Patients Treated with Regorafenib

Metastatic colorectal cancer is frequently associated with poor clinical conditions that may limit therapeutic options. Regorafenib is a small molecule approved for the treatment of metastatic colorectal cancer, but it is hampered by significative toxicities. Moreover, only a relatively limited numb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbona, Andrea, Ricci, Vincenzo, Paccagnella, Matteo, Granetto, Cristina, Ruatta, Fiorella, Cauchi, Carolina, Galizia, Danilo, Ghidini, Michele, Denaro, Nerina, Merlano, Marco Carlo, Garrone, Ornella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959285/ https://www.ncbi.nlm.nih.gov/pubmed/36851213 http://dx.doi.org/10.3390/vaccines11020335

Ejemplares similares

How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review
por: Merlano, Marco Carlo, et al.
Publicado: (2022)

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
por: Paccagnella, Matteo, et al.
Publicado: (2022)

Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy
por: Merlano, Marco Carlo, et al.
Publicado: (2021)

The Role of Cytokinome in the HNSCC Tumor Microenvironment: A Narrative Review and Our Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment
por: Merlano, Marco Carlo, et al.
Publicado: (2023)

How I treat squamous ENT cancer
por: Merlano, Marco Carlo, et al.
Publicado: (2019)

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review
por: Denaro, Nerina, et al.
Publicado: (2021)

Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
por: Barbin, Francesca, et al.
Publicado: (2022)

Heterogeneity of colon cancer: from bench to bedside
por: Merlano, Marco C, et al.
Publicado: (2017)

Thrombotic Events during Lenvatinib Treatment: A Single Institution Experience
por: Denaro, Nerina, et al.
Publicado: (2022)

Knowing the tumour microenvironment to optimise immunotherapy
por: MERLANO, M.C., et al.
Publicado: (2019)

Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study
por: Garrone, Ornella, et al.
Publicado: (2020)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

The Tumor Microenvironment and the Estrogen Loop in Thyroid Cancer
por: Denaro, Nerina, et al.
Publicado: (2023)

Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations
por: Denaro, Nerina, et al.
Publicado: (2013)

Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience
por: Denaro, Nerina, et al.
Publicado: (2016)

Long noncoding RNAs as regulators of cancer immunity
por: Denaro, Nerina, et al.
Publicado: (2018)

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
por: Denaro, Nerina, et al.
Publicado: (2021)

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
por: Denaro, Nerina, et al.
Publicado: (2023)

Immune-related response criteria: light and shadows
por: Merlano, Marco, et al.
Publicado: (2016)

Head and neck cancer: improving outcomes with a multidisciplinary approach
por: Lo Nigro, Cristiana, et al.
Publicado: (2017)

Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC)
por: Denaro, Nerina, et al.
Publicado: (2020)

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer
por: Denaro, Nerina, et al.
Publicado: (2013)

Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide
por: Merlano, Marco C., et al.
Publicado: (2018)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial
por: Xu, Jianming, et al.
Publicado: (2020)

Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
por: Lawson McLean, Aaron
Publicado: (2023)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Renal Cell Carcinoma with bone metastases isn’t always bad
por: Ruatta, Fiorella, et al.
Publicado: (2019)

Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer
por: Arai, Jun, et al.
Publicado: (2022)

Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience
por: Salati, Massimiliano, et al.
Publicado: (2023)

How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy
por: Galizia, Danilo, et al.
Publicado: (2022)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients
por: Griseri, Paola, et al.
Publicado: (2016)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Basal Cell Carcinoma and Hedgehog Pathway Inhibitors: Focus on Immune Response
por: Gambini, Donatella, et al.
Publicado: (2022)

Data on subgroup specific baseline characteristics and serum sphingosine-1-phosphate concentrations in the Study of Health in Pomerania
por: Moritz, Eileen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dvcd2dseb7pkbt8gvsng2gpba2